drugset / Trial / NCT00001123

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

NCT00001123

Double-blindTreatment

Summary

The purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. The hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. It is characterized by fever and bleeding.

Timeline

Start
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule Intravenous